BRIEF—Ontozry to be reimbursed in Ireland

Ireland’s health technology assessor, the National Centre for Pharmacoeconomics (NCPE), has confirmed a positive reimbursement decision for the oral anti-seizure med Ontozry (cenobamate).

Developed by private Italian drugmaker Angelini Pharma, Ontozry was  approved more than two years ago by the European Medicines Agency.

It was approved in the USA in 2019, where it is marketed under the Xcopri brand.

The NCPE has recommended the product’s use for the adjunctive treatment of focal onset seizures, with or without secondary generalization, in certain adults with epilepsy.

Angelini UK & Ireland’s general manager, Stuart Mulheron, said: “We are committed to bringing life-changing treatments to people living with epilepsy and are delighted to be able to bring the benefits of cenobamate to the people of Ireland.”